Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Hepion Pharmaceuticals Inc HEPA

Healthcare
Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of drug therapy for treatment of chronic liver diseases. The Company is developing a treatment for non-alcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC), and other chronic liver diseases. Its cyclophilin inhibitor, rencofilstat, is being developed to offer benefits to address... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:HEPA)

Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger

GlobeNewswire November 11, 2024

Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger

GlobeNewswire September 4, 2024

Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement

GlobeNewswire July 22, 2024

Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b 'ASCEND-NASH' Trial

GlobeNewswire April 19, 2024

Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell

GlobeNewswire March 6, 2024

Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds

GlobeNewswire February 16, 2024

Hepion Pharmaceuticals to Present at NASH-TAG 2024

GlobeNewswire January 3, 2024

Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes

GlobeNewswire December 7, 2023

Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit

GlobeNewswire November 28, 2023
View More News ››

Opinion & Analysis (NDAQ:HEPA)

ContraVir's Hep B drug could be a game changer

The Life Sciences Report February 2, 2017
View More Opinion ››

Bullboard Posts (NDAQ:HEPA)

Why Is Liver-Disease Drug Developer Hepion Pharmaceuticals S

BREAKING NEWS: $HEPA Why Is Liver-Disease Drug Developer Hepion Pharmaceuticals Stock Trading Lower On Monday? | BenzingaFriday,@Hepion...
whytestocks - April 22, 2024

Loading

Great time to buy this stock currently 1.22 what a steal.
Finalrep - November 29, 2021

HEPA - Major Buy Alert Update

<< View Post To Watch Video >>
HDavis - September 13, 2021

HEPA - Major Buy Alert

<< View Post To Watch Video >>
HDavis - September 12, 2021

Please take a look

https://www.change.org/p/fda-and-ema-improving-the-public-health?recruiter=1170861947&recruited_by_id=6f0edee0-47cf-11eb-a646...
scarlet1967 - May 26, 2021

SAVA $1.27 NASDAQ HUGE BUY ALERT!

$PECK WE ALERTED UNDER $JSYN @ $8 HIT AROUND $25++ YESTERDAY. GAVE CHANCES TO ADD PULL BACKS HIT $19 PREMARKET AND $17++ ON SECONDARY...
BerkshireCapGrp - June 21, 2019
View more Bullboard ››

Promino Nutritional Sciences Inc.

Promino Nutritional Sciences Inc.

Promino Nutritional Sciences Inc., formerly Element Nutritional Sciences Inc., is a research-driven Canadian nutraceutical ...
View More »